News Arlington Scientific, Inc. broadens product portfolio and further expands its product offering through the acquisition of Non-Mammalian Blocking Buffers
ACQUISITIONS and MERGERS
1 min.Read

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of EastCoast Bio. Arlington Scientific will now be the exclusive worldwide manufacturer of these proprietary blocking buffers for markets including In-Vitro Diagnostic (IVD) manufacturers and for research and development institutions.

“This acquisition will provide strategic value to Arlington Scientific in the form of new product markets, expansion of its manufacturing capabilities, increased sales and new customers. This is in line with ASI’s strategy of being a progressive industry leader through the pursuit of quality products, superior customer service, high corporate values, and a genuine appreciation for each customer,” said David Porter, Chief Business Development officer for Arlington Scientific.

ASI is an FDA registered establishment with over 36 years of medical device manufacturing expertise in diagnostic reagents and serological test kits. ASI is at the forefront of innovation and was the first to develop an automated nontreponemal algorithm for the detection of syphilis; the first to develop the only automated nontreponemal (RPR) syphilis analyzer FDA cleared for diagnostic, blood donor screening and cadaveric (non-heartbeating) donor screening; the first to include mercury free RPR reagents, implementation of liquid controls, screw cap lids, warp resistant test cards, extended shelf life for reagents and developing in-vitro diagnostic RPR tests for use with CPD and CPDA-1 anticoagulants.

Product Overview:

Balance Blocking Buffer (ELISA/WB/Lateral Flow)Universal blocking reagent provides superior blocking in sensitive assay systems (Available in three formulations, with PBS, PBS with a surfactant or with Tris).
• Aquatic Block™ Serum Free – Formerly called SeaBlock Serum Free (Lateral Flow/ELISA)Serum and plasma-free optimized for use with nitrocellulose in lateral flow assays and ELISA systems (Available in two formulations, with PBS or Tris).
• Aquatic Block™ – Formerly called SeaBlock(ELISA/EIA/WB)Formulated for ELISA assay development. Can be diluted to 1:1 to 1:50 to reduce signal-to-noise ratio (Available in two formulations, with PBS or Tris).
• AquaBlock (WB/EIA/Chemiluminescence)Significantly reduces non-specific protein attachment when used with a blotting membrane.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330